<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020329</url>
  </required_header>
  <id_info>
    <org_study_id>NPC in Young Patients</org_study_id>
    <nct_id>NCT03020329</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Phase II Study of Induction Chemotherapy (Taxol+Cisplatin+Fluorouracil) Plus Concurrent Chemoradiotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To see the effect if a combination of induction chemotherapy followed by chemoradiotherapy
      works in treating children with advanced nasopharyngeal carcinoma(NPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II trial is studying how well radiation therapy and chemotherapy work in treating
      young patients with newly diagnosed nasopharyngeal cancer. Radiation therapy uses high-energy
      x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil
      and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing
      the cells or by stopping them from dividing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR)</measure>
    <time_frame>After the completion of the chemoradiotherapy treatment (up to 9 weeks)</time_frame>
    <description>CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI). Disease response evaluated after the completion of the chemoradiotherapy treatment. Complete response defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>3-year</time_frame>
    <description>The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival(PFS)</measure>
    <time_frame>3-year</time_frame>
    <description>Progress-free survival is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival(LRFS)</measure>
    <time_frame>3-year</time_frame>
    <description>The LRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival(DMFS)</measure>
    <time_frame>3-year</time_frame>
    <description>The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term toxic effects assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)</measure>
    <time_frame>3 months</time_frame>
    <description>The shortterm toxic effects were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term toxicities</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term toxicities</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>EORTC quality of life questionnaire(QLQ) Head and Neck</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Patients will be monitored for height(in metre)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Patients will be monitored for weight(in kilogram)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Patients will be monitored for BMI(in kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex Development</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Sex hormone(estrogen,testosterone) levels(in nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex Development</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Secondary sex characteristic survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intelligence Development</measure>
    <time_frame>Through study completion, an average of half year</time_frame>
    <description>Intelligence quotient by Stanford-Binet test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, Cisplatin, 5-Fu,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel (135mg/m2 on day 1), cisplatin (70mg/m2 on day 1) and fluorouracil (700mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy(Intensive modulate radiotherapy,IMRT)and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Patients receive paclitaxel (135mg/m2 on day 1),cisplatin (70mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (700mg/m2 on Days 1 to 5) every three weeks for three cycl es before the radiotherapy.
Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:61.2Gy/34F,1.8Gy/daily.</description>
    <arm_group_label>Paclitaxel, Cisplatin, 5-Fu,</arm_group_label>
    <other_name>Paclitaxel,cisplatin,fluorouracil(TPF) chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin (70mg/m2 Separate injection on day 1 to 3) with Paclitaxel and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2)Separate injection every three weeks for three cycles during radiotherapy.</description>
    <arm_group_label>Paclitaxel, Cisplatin, 5-Fu,</arm_group_label>
    <other_name>TPF induction chemotherapy</other_name>
    <other_name>Concurrent cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fu</intervention_name>
    <description>Fluorouracil (700mg/m2 on Days 1 to 5)with Paclitaxel and cisplatin every three weeks for three cycles before the radiotherapy.</description>
    <arm_group_label>Paclitaxel, Cisplatin, 5-Fu,</arm_group_label>
    <other_name>TPF induction chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radical radiotherapy</intervention_name>
    <description>Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:61.2Gy(Gray)/34F(Fraction),1.8Gy/daily,5 days/week.</description>
    <arm_group_label>Paclitaxel, Cisplatin, 5-Fu,</arm_group_label>
    <other_name>Concurrent radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed non-keratinizing (according to World
             Health Organization (WHO) histologically type).

          -  Original clinical staged as T4N0-3 M0 or any T、N3M0（according to the American Joint
             Committee on Cancer(AJCC) 7th edition）

          -  No evidence of distant metastasis (M0).

          -  Age ≤ 18 years old.

          -  Satisfactory performance status: Karnofsky scale (KPS) &gt; 70.

          -  Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count
             ≥100000/μL.

          -  Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)
             ≤2.5×ULN, and bilirubin ≤ULN.

          -  Adequate renal function: creatinine clearance ≥60 ml/min.

          -  Patients must be informed of the investigational nature of this study and give written
             informed consent.

        Exclusion Criteria:

          -  WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.

          -  Age &gt;18 years.

          -  Treatment with palliative intent.

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in
             situ cervical cancer.

          -  Pregnancy or lactation.

          -  History of previous radiotherapy (except for non-melanomatous skin cancers outside
             intended RT treatment volume).

          -  Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose
             &gt;1.5×ULN), and emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HaiQiang Mai, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DongHua Luo, MD,PhD</last_name>
    <phone>8620-87343643</phone>
    <email>luodh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HaiQiang Mai, PhD</last_name>
      <phone>8620-38606186</phone>
      <email>maihq@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>cisplatin</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>amifostine</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>paclitaxel</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>fluorouracil</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>nasopharyngeal carcinoma</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>young patients</description>
  </link>
  <reference>
    <citation>Daoud J, Ghorbal L, Siala W, Elloumi F, Ghorbel A, Frikha M. [Is there any difference in therapeutic results of nasopharyngeal carcinoma between adults and children?]. Cancer Radiother. 2013 Dec;17(8):763-7. doi: 10.1016/j.canrad.2013.06.046. Epub 2013 Nov 20. French.</citation>
    <PMID>24269016</PMID>
  </reference>
  <reference>
    <citation>Yan Z, Xia L, Huang Y, Chen P, Jiang L, Zhang B. Nasopharyngeal carcinoma in children and adolescents in an endemic area: a report of 185 cases. Int J Pediatr Otorhinolaryngol. 2013 Sep;77(9):1454-60. doi: 10.1016/j.ijporl.2013.06.005. Epub 2013 Jul 3.</citation>
    <PMID>23830224</PMID>
  </reference>
  <reference>
    <citation>Liao WW, Tang SQ, Liu Y, Feng C. [Treatment of nasopharyngeal carcinoma in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2013 Apr;15(4):273-6. Chinese.</citation>
    <PMID>23607949</PMID>
  </reference>
  <reference>
    <citation>Hu S, Xu X, Xu J, Xu Q, Liu S. Prognostic factors and long-term outcomes of nasopharyngeal carcinoma in children and adolescents. Pediatr Blood Cancer. 2013 Jul;60(7):1122-7. doi: 10.1002/pbc.24458. Epub 2013 Jan 9.</citation>
    <PMID>23303571</PMID>
  </reference>
  <reference>
    <citation>Cheuk DK, Billups CA, Martin MG, Roland CR, Ribeiro RC, Krasin MJ, Rodriguez-Galindo C. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011 Jan 1;117(1):197-206. doi: 10.1002/cncr.25376. Epub 2010 Aug 24.</citation>
    <PMID>20737561</PMID>
  </reference>
  <reference>
    <citation>Buehrlen M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P, Staatz G, Gademann G, Christiansen H, Oldenburger F, Tamm M, Mertens R. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012 Oct 1;118(19):4892-900. doi: 10.1002/cncr.27395. Epub 2012 Feb 22.</citation>
    <PMID>22359313</PMID>
  </reference>
  <reference>
    <citation>Shen C, Gao Y, Xu T, Wang X, Ying H, Hu C. Carcinoma of the nasopharynx in young patients: a single institution experience. Clin Oncol (R Coll Radiol). 2009 Oct;21(8):617-22. doi: 10.1016/j.clon.2009.07.005. Epub 2009 Aug 5.</citation>
    <PMID>19660923</PMID>
  </reference>
  <reference>
    <citation>Varan A, Ozyar E, Corapçioğlu F, Köksal Y, Aydin B, Yazici N, Akyüz C, Büyükpamukçu M. Pediatric and young adult nasopharyngeal carcinoma patients treated with preradiation Cisplatin and docetaxel chemotherapy. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1116-20. doi: 10.1016/j.ijrobp.2008.05.028. Epub 2008 Sep 9.</citation>
    <PMID>18786778</PMID>
  </reference>
  <reference>
    <citation>Laskar S, Bahl G, Muckaden M, Pai SK, Gupta T, Banavali S, Arora B, Sharma D, Kurkure PA, Ramadwar M, Viswanathan S, Rangarajan V, Qureshi S, Deshpande DD, Shrivastava SK, Dinshaw KA. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):728-36. doi: 10.1016/j.ijrobp.2008.01.032. Epub 2008 Apr 18.</citation>
    <PMID>18374512</PMID>
  </reference>
  <reference>
    <citation>Selek U, Ozyar E, Ozyigit G, Varan A, Buyukpamukcu M, Atahan IL. Treatment results of 59 young patients with nasopharyngeal carcinoma. Int J Pediatr Otorhinolaryngol. 2005 Feb;69(2):201-7.</citation>
    <PMID>15656953</PMID>
  </reference>
  <reference>
    <citation>Orbach D, Brisse H, Helfre S, Klijanienko J, Bours D, Mosseri V, Rodriguez J. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: Radiotherapy dose adaptation after chemotherapy response to minimize late effects. Pediatr Blood Cancer. 2008 Apr;50(4):849-53.</citation>
    <PMID>17973328</PMID>
  </reference>
  <reference>
    <citation>Ahern V, Jenkin D, Banerjee D, Greenberg M, Payne D. Nasopharyngeal carcinoma in the young. Clin Oncol (R Coll Radiol). 1994;6(1):24-30.</citation>
    <PMID>8172830</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hai-Qiang Mai,MD,PhD</investigator_full_name>
    <investigator_title>Professor and Deputy Director</investigator_title>
  </responsible_party>
  <keyword>Induction Chemotherapy</keyword>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

